Cerus (NASDAQ:CERS) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Cerus Corporation (NASDAQ:CERS) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.56 and traded as high as $2.13. Cerus shares last traded at $2.06, with a volume of 858,664 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on CERS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cerus in a report on Wednesday, October 8th. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cerus presently has an average rating of “Hold” and a consensus target price of $4.00.

Cerus Stock Performance

The firm has a market capitalization of $395.71 million, a P/E ratio of -25.75 and a beta of 1.52. The stock has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.57. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.89 and a quick ratio of 1.29.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.02. Cerus had a negative net margin of 8.01% and a negative return on equity of 27.58%. The firm had revenue of $60.24 million during the quarter, compared to the consensus estimate of $55.12 million. On average, research analysts predict that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Trading of Cerus

A number of hedge funds and other institutional investors have recently bought and sold shares of CERS. Cubist Systematic Strategies LLC increased its holdings in Cerus by 152.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 62,854 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Cerus by 291.6% during the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after buying an additional 1,064,133 shares during the last quarter. Millennium Management LLC grew its holdings in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after buying an additional 344,395 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus in the 1st quarter valued at $32,000. Finally, Acadian Asset Management LLC lifted its stake in Cerus by 112.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company’s stock valued at $2,637,000 after acquiring an additional 1,005,079 shares in the last quarter. Institutional investors own 78.37% of the company’s stock.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.